Membrane Transporters-Ion Channels

Items 751-800 of 2532

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. KATP channel activator

    P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation.
  2. Nav1.7 inhibitor

    PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM.
  3. Pgp modulator

    P-gp modulator 1 is a high affinity, orally available modulator of P-glycoprotein (Pgp), can reverse the Pgp-mediated multidrug resistance ((MDR).
  4. Kv7.2/Kv7.4 channels activator

    ML213 is a selective activator of Kv7.2 and Kv7.4 channels, enhances Kv7.2 and Kv7.4 channels with EC50s of 230 and 510 nM, respectively.
  5. Cl- conductance/hKCa3.1 channel activator

    DCEBIO, a derivative of 1-EBIO, is an extremely potent activator of Cl?? secretion in T84 colonic cells.
  6. CFTR modulator

    Elexacaftor (VX-445, Compound 1) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR).
  7. potassium channel blocker

    Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current.
  8. ENT1 inhibitor

    Draflazine (R-75231) is a ENT1 inhibitor.
  9. TRPC3 inhibitor

    Pyr3 is a selective inhibitor of transient receptor potential canonical channel 3 (TRPC3), with an IC50 of 700 nM for TRPC3-mediated Ca2+ influx.
  10. AMPAR negative modulator

    JNJ-61432059 is an oral active and selective negative modulator of AMPAR associated with trans-membrane AMPAR regulatory protein (TARP) γ-8, with a pIC50 of 9.7 for GluA1/γ-8.
  11. lipophilic calcium channel blocker

    Teludipine is a lipophilic calcium channel blocker.
  12. KCa3.1 activator

    SKA-121 is a selective KCa3.1 activator. SKA-121 exhibits EC50s of 109 nM and 4.4 μM for KCa3.1 and KCa2.3, respectively.
  13. CFTR amplifier

    PTI-428 is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier.
  14. ABCG2 inhibitor

    ML230 (CID44640177; SID 88095709) is a selective inhibitor of ATP-binding cassette (ABC) transporter ABCG2, and 36-fold selective for ABCG2 over ABCB1 with EC50s values of 0.13 μM and 4.65 μM, respectively.
  15. IKs blocker

    HMR 1556, a chromanol derivative, is a IKs blocker with IC50s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively.
  16. tropomyosin inhibitor

    ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
  17. kainate receptors agonist

    SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively.
  18. TRPV1 receptor antagonist

    JYL 1421 is a TRPV1 receptor antagonist, with an IC50 of 8 nM.
  19. cyanoguanidine KATP opener

    Naminidil is a cyanoguanidine KATP opener.
  20. broad-spectrum arenavirus inhibitor

    ST-193 is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
  21. Na+ blocker

    Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain.
  22. sodium channel blocker

    Sodium Channel inhibitor 2 is a sodium channel blocker extracted from patent WO 2004011439 A2, compound 3c.
  23. Ca2+ Channel Blocker

    NS-638 is a small nonpeptide molecule with Ca2+-channel blocking properties. K+-stimulated intracellular Ca2+-elevation is blocked with an IC50 value of 3.4 μM.
  24. proton pump inhibitor

    Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138.
  25. IK blocker

    AM-92016 hydrochloride is a specific blocker of rectifier potassium current (IK).
  26. intravenous BKCa-channel blocker

    GAL-021 a new intravenous BKCa-channel blocker.
  27. DHBP dibromide is an inhibitor for calcium release and a muscle relaxant.
  28. anion conductance inhibitor

    NS1652 is a reversible anion conductance inhibitor, blocks chloride channel, with an IC50 of 1.6 μM in human and mouse red blood cells.
  29. AMPA receptor modulator

    Org-26576 is a AMPA receptor positive allosteric modulator.
  30. CFTR corrector

    CFTR corrector 2 is a cystic fibrosis transmembrane conductance corrector (CFTR), extracted from patent US20140274933.
  31. Nav1.7/Nav1.8 blocker

    DSP-2230 is a selective Nav1.7/Nav1.8 blocker.
  32. potassium channel blocker

    VU0134992 is a selective inward rectifier potassium (Kir) channel Kir4.1 blocker with an IC50 of 0.97 ?M.
  33. MCT1 inhibitor

    BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity.
  34. EAAT2 modulator

    GT 949 is a selective excitatory amino acid transporter-2 (EAAT2) positive allosteric modulator with an EC50 of 0.26 nM.
  35. Kv3 potassium channel modulator

    AUT1 is a Kv3 potassium channel modulator with pEC50s of 5.33 and 5.31 for human recombinant Kv3.1b and Kv3.2a, respectively, exhibits 10-fold lower potency at human recombinant Kv3.3 channel (pEC50, 4.5).
  36. URAT1 inhibitor

    URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC50 of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout.
  37. SGLT1 inhibitor

    SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively.
  38. NaV1.8 blocker

    PF-06305591 is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile.
  39. L-Palmitoylcarnitine is a fatty acid metabolite.
  40. Sodium channel blocker

    Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker.
  41. SLC13A5 inhibitor

    BI01383298 is a potent inhibitor of SLC13A5, being selective over other family members and other transporters.
  42. Iron mobilizer

    Guanosine 5'-diphosphate is a nucleoside diphosphate. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulating the interleukin-6 (IL-6)/stat-3 pathway.
  43. Na+/H+ exchanger inhibitor

    5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na+/H+ exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells.
  44. CFTR potentiator

    GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, which effectively potentiates low temperature rescued F508del CFTR with an EC50 of 11.1 nM.
  45. NaV 1.7 inhibitor

    NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5.
  46. Kv3.1/Kv3.2 modulator

    Kv3 modulator 4 is a Kv3.1 (pEC50=5.45) and Kv3.2 modulator extracted from patent WO2018020263A1, Cyclobutyl structure.
  47. Kv3.1/Kv3.2/Kv3.3 channels modulator

    Kv3 modulator 3 (Compound 4) is a selective modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels extracted from patent WO2017098254A1, compound 4, has analgesic activity for use in the prophylaxis o or treatment of pain.
  48. nucleoside transport inhibitor

    Soluflazine is a nucleoside transport inhibitor with anticonvulsant action. Soluflazine can be used as an antiepileptic agent.
  49. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
  50. Nav1.7 inhibitor

    GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (Ki of 0.79 nM and Kd of 0.38 nM for hNav1.7) for the treatment of chronic pain.

Items 751-800 of 2532

Page
per page
Set Descending Direction